BioFINDER is an ongoing Swedish longitudinal program focused on multimodal biomarker discovery and validation across the AD spectrum, with MRI, amyloid PET, tau PET, FDG-PET, CSF, and cognitive testing; BioFINDER-2 includes large prospective cohorts spanning CU through dementia and reports with ~1400–2000 participants across recent publications/registries. The gene discussed is MAPT; the disease is Alzheimer disease.